AbbVie (ABBV) Acquires Apogee for $10.9 Billion Eczema Drug
Published on Β· Source: marketwatch.com
AI Summary
Summarized by AI from the source belowAbbVie (ABBV) announced its acquisition of Apogee Therapeutics for $10.9 billion. The focus of this acquisition is Apogee's development of an experimental drug for atopic dermatitis, a type of eczema. This move is significant for AbbVie as it expands its portfolio in dermatological treatments. The transaction underscores the ongoing trend of consolidations in the biotech sector to enhance product pipelines.
Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.
Get the weekly market brief
One email every Monday: what moved, why, and what to watch. Free, unsubscribe anytime.
Related News
M&A
Brookfield Business (BBUC) Joins $2.8 Billion Reliance Acquisition Deal
Sep 20
Earnings
Lindblad Expeditions (LIND) Acquires 60% of White Desert for $61M
Sep 20
M&A
SPXC Acquires FIS Water for $410M to Boost Cooling Revenue
Sep 20
M&A
NextEra Energy (NEE) and Dominion (D) Propose $1 Billion Benefits Package
Sep 20